TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma.

Saved in:
Bibliographic Details
Title: TREM-1 as a novel immunotherapeutic target to treat pancreatic ductal adenocarcinoma.
Authors: Gross L; Christine Kühne - Center for Allergy Research and Education, 7265 Davos, Switzerland.; Graduate School Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland., Mutisheva I; Division of Experimental Pathology, Institute of Tissue Medicine and Pathology, University of Bern, 3008 Bern, Switzerland., Hillen H; Division of Experimental Pathology, Institute of Tissue Medicine and Pathology, University of Bern, 3008 Bern, Switzerland., Robatel S; Graduate School Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.; Division of Experimental Pathology, Institute of Tissue Medicine and Pathology, University of Bern, 3008 Bern, Switzerland., Wartenberg M; Division of Surgical Pathology, Institute of Tissue Medicine and Pathology, University of Bern, 3008 Bern, Switzerland., Ma F; Department of Cell and Developmental Biology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA., Bäriswyl L; Division of Experimental Pathology, Institute of Tissue Medicine and Pathology, University of Bern, 3008 Bern, Switzerland., Lee DJ; The Lundquist Institute for Biomedical Innovation, Torrance, CA 90502, USA.; Division of Dermatology, Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Modlin RL; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.; Division of Dermatology, School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA., Z'graggen K; Swiss Pancreas Clinic, 3013 Bern, Switzerland., Schenk M; Christine Kühne - Center for Allergy Research and Education, 7265 Davos, Switzerland.; Division of Experimental Pathology, Institute of Tissue Medicine and Pathology, University of Bern, 3008 Bern, Switzerland.
Source: Molecular therapy. Oncology [Mol Ther Oncol] 2025 Aug 14; Vol. 33 (3), pp. 201034. Date of Electronic Publication: 2025 Aug 14 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918752083706676 Publication Model: eCollection Cited Medium: Print ISSN: 2950-3299 (Print) Linking ISSN: 29503299 NLM ISO Abbreviation: Mol Ther Oncol Subsets: In Process
Database: MEDLINE Ultimate
Description
ISSN:2950-3299
DOI:10.1016/j.omton.2025.201034